Idorsia Ltd. is a biopharmaceutical company headquartered in Allschwil, Switzerland, focused on the discovery, development and commercialization of innovative small-molecule therapies. Established in 2017 as a spin-off from Actelion Pharmaceuticals, the company maintains a research-driven model aimed at advancing compounds through clinical trials to address unmet medical needs in areas such as sleep disorders, cardiovascular disease, immunology and other specialty fields.
One of Idorsia’s leading products is daridorexant (commercial name Quviviq), a dual orexin receptor antagonist approved in several regions for the treatment of insomnia, reflecting the company’s commitment to neuroscience and central nervous system disorders. In addition to sleep medicine, the firm’s pipeline includes candidates targeting hypertension, heart failure and pulmonary arterial hypertension, each at various stages of clinical development. By leveraging structure-based design and in-house screening platforms, Idorsia seeks to optimize selectivity and safety profiles for its investigational compounds.
Idorsia operates globally, with a commercial presence in North America, Europe and Asia Pacific. The company’s manufacturing and clinical trial management capabilities span multiple geographies, allowing for efficient progression from early-stage research to regulatory submissions and market launch. Strategic partnerships and collaborations support Idorsia’s efforts to expand access to its therapies and to co-develop new chemical entities in complementary therapeutic areas.
Leadership at Idorsia is headed by CEO Jean-Paul Clozel, one of the original founders, who brings decades of experience in drug discovery and development. Under his guidance, the company has built a multidisciplinary team of scientists, clinicians and business professionals committed to advancing next-generation treatments. Idorsia’s long-term strategy centers on balancing a robust proprietary pipeline with selective external collaborations to maximize the impact of its R&D investments.
AI Generated. May Contain Errors.
